Dendritic cell vaccine - Tella

Drug Profile

Dendritic cell vaccine - Tella

Alternative Names: Dendritic-cell-vaccine-Tella; MUC1-WT1-peptide-loaded-dendritic-cell-vaccine-Tella; Peptide-pulsed-dendritic-cell-vaccine-Tella; TLP0-001; Tumour peptide-pulsed dendritic cell vaccine - Tella; Vaccell - Tella

Latest Information Update: 04 May 2017

Price : $50

At a glance

  • Originator Tella
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I/II Biliary cancer; Malignant melanoma
  • Phase I Liver cancer; Oesophageal cancer
  • Research Allergic rhinitis; Autoimmune disorders

Most Recent Events

  • 14 Mar 2017 Phase-III clinical trials in Pancreatic cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in Japan (Parenteral) (UMIN000027179)
  • 22 Feb 2016 Tumour peptide pulsed dendritic cell vaccine is still in phase I/II trials for Pancreatic cancer, Biliary cancer and Malignant melanoma in Japan
  • 03 Apr 2015 Interim efficacy and adverse events data from a phase I trial in Pancreatic cancer released by Tella
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top